

Attorney.

In the Abstract:

Replace the current abstract, which consists of two paragraphs on page 96, with the following new abstract, consisting of one paragraph.

C2 The invention provides primary and secondary cells that are transfected with a nucleic acid molecule that encodes erythropoietin, clonal or heterogenous strains of such cells, and methods of producing these cell strains.

In the Claims:

Cancel claims 134, 135, 147, 148, 160, 161, 173, and 174, and amend claims 108-133, 139, 141, 143, 144, 146, 152, 154, 156, 157, 159, 165, 167, 169, 170, 172, 178, 180, 182, and 183 as follows.

108. (Amended) A transfected primary or secondary cell having stably integrated into its genome:

- C3
- a) exogenous DNA that encodes erythropoietin, and
 - b) DNA sequences that direct expression of the exogenous DNA in the primary or secondary cell.